In the present study, we examined the inhibitory effect of melatonin and its possible mechanisms in hypoxia-mediated TRAIL resistant tumor cells and also suggested that melatonin may be a therapeutic strategy for anti-cancer therapy in combination with TRAIL, particularly in solid tumor cells exposed to hypoxia. The gene discussed is TNFSF10; the disease is neoplasm.